Direct tumor injection of a modified adenovirus for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase I interventional study evaluates the safety and maximum tolerated dose of RGDCRAdCOX2F, a modified adenovirus, administered directly into tumors of patients with adenocarcinoma of the pancreas. The trial aims to determine the maximum desired toxicity level while assessing the feasibility of the treatment approach. Participants must have histologically confirmed pancreatic adenocarcinoma that is localized and accessible for injection. The study is conducted at a single center, the Masonic Cancer Center at the University of Minnesota.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically documented pancreatic adenocarcinoma that is confined to the pancreas and regional lymph nodes after staging by CT or MRI and endoscopic ultrasound.
* One prior line of therapy is permitted (i.e. neo-adjuvant therapy); however, at least 4 weeks must have elapsed between the last dose of drug and the injection of RGDCRAdCOX2F.
* Must be able to tolerate esophagogastroduodenoscopy (EGD) and the tumor must be accessible by endoscopic ultra sound. Participants will be excluded if obtaining biopsies are deemed unsafe or not feasible.
* Age 18 years of age or older at the time of consent
* Normal cardiac and pulmonary function based on history and physical exam
* Participants with partners of childbearing potential must be willing to use at least two forms of effective birth control (one form must be a barrier method) for at least 1 month after Day 1.

Exclusion Criteria:

* Pregnant or breastfeeding. Persons of child-bearing potential must have a negative pregnancy test (serum or urine) with 14 days of study enrollment.
* Other pancreatic malignancies (e.g., neuroendocrine tumors and mucinous cystic) and adenocarcinomas of the ampulla, bile ducts, and duodenum.
* Tumors in mucosal regions or close to an airway, major blood vessel, or spinal cord that in the opinion of the enrolling investigator could cause occlusion or compression in the case of tumor swelling or erosion into a major vessel in the case of necrosis.
* Known history of human immunodeficiency virus (HIV) infection
* Known history of or active acute or chronic active hepatitis B or C infection
* Serious concurrent infection or medical illness, which in the enrolling investigator's opinion would jeopardize the ability of the participant to receive the treatment outlined in this protocol with reasonable safety.
* Requires immunosuppression ≥10mg/day of prednisone for more than

  1 week.
* History of or active known or suspected autoimmune disease, or a syndrome that requires systemic or immunosuppressive agents.
* Disease beyond the regional lymph nodes
* Active diffuse pancreatitis
* Active inflammatory conditions
* Prior gastrojejunostomy

Where it's running

• Masonic Cancer Center
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Edward Greeno, MD
• Email: green048@umn.edu
• Phone: 612-626-6418

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hepatic artery infusion therapy for liver metastases after pancreatic/duodenal cancer surgery

  This study tests whether delivering chemotherapy directly to the liver via a pump can help people with pancreatic or duodenal cancer that has spread mainly to the liver after surgery and prior chemotherapy.

  Recruiting AdventHealth · Orlando, Florida · NCT07845617

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• THE-0504 in patients with solid tumors

  A first-in-human, dose-escalation study to see if THE-0504 is safe and tolerable in adults with solid tumors such as SCLC, CRC, GC, TNBC, and pancreatic cancer.

  Recruiting Phase 1 Thena Biotech S.r.l. · Rome, Lazio · NCT07646106

• Planned surgery or focused local treatment after chemo for metastatic upper-GI adenocarcinoma with undetectable ctDNA

  This test sees if adding planned surgery or local treatments after three months of chemotherapy helps people with metastatic upper-gastrointestinal adenocarcinomas who have undetectable ctDNA.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT07282912

• Preventing complications after high-risk Whipple (pancreatoduodenectomy) with hydrocortisone, octreotide, and a teres ligament patch

  This tests whether giving hydrocortisone and octreotide around surgery plus placing a teres ligament patch can lower major complications after Whipple surgery in patients with a small pancreatic duct.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07262957

• Neoadjuvant chemotherapy versus immediate surgery for resectable pancreatic head and periampullary cancer

  This trial tests if giving chemotherapy before surgery helps people with resectable pancreatic head or periampullary cancer live longer than having immediate surgery followed by chemotherapy.

  Recruiting Phase 3 Minia University · Minya, Minya Governorate · NCT07081360

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.